Popular terms

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      

This page is updated frequently with new Platelet-related patent applications.




Date/App# patent app List of recent Platelet-related patents
02/04/16
20160036081 
 Graphene-based proton exchange membrane for direct methanol fuel cells patent thumbnailGraphene-based proton exchange membrane for direct methanol fuel cells
A proton exchange membrane (pem) for use in a direct methanol fuel cell (dmfc) is a laminate of graphene oxide (go) or sulfonated graphene oxide (sgo) platelets. The mean size of the platelets is at least 10 μm in diameter and the platelets are combined as a laminate.
University Of Florida Research Foundation, Inc.


02/04/16
20160033475 
 Platelet aggregation test and device patent thumbnailPlatelet aggregation test and device
An assembly for testing platelet aggregation including an electrode subassembly that is mounted in a cuvette subassembly for use with relatively small samples containing platelets.. .
Chrono-log Corporation


02/04/16
20160032061 
 Polymer-graphene nanocomposites patent thumbnailPolymer-graphene nanocomposites
Provided herein is technology relating to polymer-graphene nanocomposites and particularly, but not exclusively, to methods for producing polymer-graphene nanocomposites using master batches comprising graphene and a polymer or polymer precursor. The resulting polymer-graphene nanocomposites comprise a high degree of exfoliation and dispersion of graphene nanoplatelets within the polymer matrix..
Xolve, Inc.


02/04/16
20160030977 
 High gas barrier thin films through ph manipulation of clay patent thumbnailHigh gas barrier thin films through ph manipulation of clay
Bilayers of a polycation and a platelet suspension on a substrate demonstrate significant oxygen barrier properties by altering the ph of the platelet. When the lower ph platelet suspension contacts deposited polycation, more positive charge is created and more platelet suspension is deposited, thereby leading to a thicker film with better gas barrier properties..
Texas A&m University


02/04/16
20160030661 
 Blood separation container for extracting self-platelet patent thumbnailBlood separation container for extracting self-platelet
According to the present invention, since a second coupling portion is formed at a release prevention member coupled to a lower portion of a main body in a prp separation container, and an ascending member having a bolt structure is screwed to the second coupling portion to ascend a lower cover disposed in a lower fluid chamber of the main body, a separate second main body is unnecessary unlike the related art. Therefore, the prp separation container is easy to carry, manufacturing costs can be reduced to thereby ensure competitive price, and a prp can be easily separated and extracted..

02/04/16
20160030371 
 Compounds and methods for delivery of prostacyclin analogs patent thumbnailCompounds and methods for delivery of prostacyclin analogs
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation


01/28/16
20160027427 
 Sound attenuating structures patent thumbnailSound attenuating structures
A sound attenuation panel is configured with a substantially acoustically transparent planar, rigid frame divided into a plurality of individual, substantially two-dimensional cells. A sheet of a flexible material is fixed to the rigid frame, and a plurality of platelets fixed to the sheet of flexible material such that each individual cell of the plurality of cells is provided with a respective platelet to establish a resonant frequency, the resonant frequency defined by the planar geometry of the individual cells, the flexibility of the flexible material and the platelets.
The Hong Kong University Of Science And Technology


01/28/16
20160025738 
 Prognostic marker to determine the risk for early-onset preeclampsia patent thumbnailPrognostic marker to determine the risk for early-onset preeclampsia
The present application relates to an in vitro method for identifying a pregnancy related syndrome selected from the group consisting of pre-eclampsia, eclampsia, hemolysis elevated liver enzymes and low platelets (hellp) and intra-uterine growth restriction (iugr), the method including (i) measuring the amount of esm-1 in a biological fluid sample from a pregnant subject, wherein the pregnant subject is between week 1 to 20 of gestation; (ii) comparing said amount of esm-1 to a reference value, and (iii) identifying the subject as being likely to have or develop the pregnancy related syndrome based on a comparison of the amount of esm-1 to the reference value. A device and a kit for identifying such a pregnancy related syndrome are also claimed..
Iq Products B.v.


01/28/16
20160022779 
 Activators of cxcr3 for the treatment of angiopathies of the eye patent thumbnailActivators of cxcr3 for the treatment of angiopathies of the eye
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the c-terminal α-helix of ip-10.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/28/16
20160022736 
 Methods for production of platelets from pluripotent stem cells and compositions thereof patent thumbnailMethods for production of platelets from pluripotent stem cells and compositions thereof
Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hescs) and induced pluripotent stem cells (ipscs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells.
Advanced Cell Technology, Inc.


01/21/16
20160018313 

Method for hematology analysis


A method whereby one or more fluorescent dyes are used to bind and stain nucleic acids in certain blood cells, such as, for example, white blood cells, nucleated red blood cells, and reticulocytes, and to induce fluorescent emissions upon excitation of photons from a given source of light, such as, for example, a laser, at an appropriate wavelength. More particularly, this invention provides a method whereby a fluorescent trigger is used in a data collection step for collecting events that emit strong fluorescence, in order to separate white blood cells and nucleated red blood cells from red blood cells and platelets without the need for using a lysing agent..
Abbott Laboratories


01/21/16
20160018028 

High pressure gas hose and making same


A high pressure gas hose and related methods of transporting high pressure gases in which gas permeability throughout a length of the high pressure gas hose is reduced. The high pressure gas hose can have an outer tube and the inner tube.
Titeflex Commercial, Inc.


01/21/16
20160017010 

Methods and compositions for delivering interleukin-1 receptor antagonist


Methods and compositions generating and using an interleukin-1 receptor antagonist (il-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist.
Biomet Biologics, Llc


01/21/16
20160015833 

Heteromultivalent particle compositions


A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.. .
Case Western Reserve University


01/21/16
20160015721 

Compositions and methods for cartilage repair


Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies..
Regenerative Sciences, Llc


01/14/16
20160012936 

Graphene printed pattern circuit structure


Disclosed is a graphene printed circuit pattern structure including a substrate excellent in electrical insulation and a graphene printed circuit layer provided on the substrate. The graphene printed circuit layer is electrically conductive and has a circuit pattern like an electrical circuit on the circuit board.
Enerage Inc.


01/14/16
20160009975 

Thermal interface material with mixed aspect ratio particle dispersions


An electron package includes an interface member between an electronic component and a thermal dissipation member. The interface member is highly efficient in transmitting thermal energy and/or suppressing electromagnetic radiation, with a particle filler dispersion including a combination of substantially spherical particles and substantially platelet-shaped particles within dispersion attribute ranges..
The Bergquist Company


01/14/16
20160009801 

Specific binding agents of glycoprotein ib alpha as selective ectodomain shedding inhibitors


This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind glycoprotein ib alpha (gpiba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications.
Children's Healthcare Of Atlanta, Inc.


01/14/16
20160009776 

Pdgfrbeta-fc fusion proteins and uses thereof


The present disclosure provides pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of pdgfrbeta, or a biologically active fragment thereof, a linker and a fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g.
Bayer Pharma Aktiengesellschaft


01/14/16
20160008490 

Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia


The present invention is directed to compounds that bind to glycoprotein iib/iiia and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein iib/iiia receptor combined with an adequate relaxivity..
Bayer Pharma Aktiengesellschaft


01/14/16
20160008416 

Formulations for preventing and treating decreasing platelet cell counts


The invention provides formulations to prevent or treat decreasing platelet cell counts. The formulations essentially consist of peanut skins, papaya leaves, folic acid, vitamin b12, vitamin c, vitamin d, vitamin e, selenium, and iron.

01/14/16
20160007713 

Aluminum-containing high gloss coating for natural and artificial fingernails


A decorative laminate for natural or artificial fingernails having at least one internal layer formed from a dried film former-free suspension of aluminum platelets.. .
Mycone Dental Supply Company, Inc.


01/07/16
20160002599 

Production methods for megakaryocytes and platelets


(ii) arresting forced expression of the apoptosis suppression gene and the oncogene and culturing the hematopoietic progenitor cells.. .

01/07/16
20160002598 

Device and methods for platelet lysis or activation


Device, system and method embodiments are disclosed herein which provide for the production of a modified autologous platelet solution at the patient bedside for contemporaneous reinjection to the patient. In certain embodiments all of the steps including, but not limited to blood draw, platelet lysis, solution preparation and reinjection to a patient may be accomplished in a single office or clinic visit without relocating the patient.
Regenerative Science, Llc


01/07/16
20160002586 

Megakaryocyte and platelet production from stem cells


Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.. .
New York Blood Center, Inc.


01/07/16
20160002056 

Synthetic zinc hectorite via hydrothermal preparation


This invention relates to synthetically derived zinc hectorite platelets, of superior platelet diameter, effect pigments comprising such synthetically derived platelets and methods of forming said substrates. More specifically the disclosure describes an improved hydrothermal synthesis of zinc hectorite suitable as a platelet for interference pigments, barrier and flame retardant applications..
Basf Se


01/07/16
20160000700 

Method for promoting hair growth


A hair growth composition prepared from a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, which has from 1,000 to 15,000 platelets in every milliliter of the hair growth composition. The present invention also provides a method for treating a bald or thin hair area due to hair loss on the head of a human by administering the hair growth composition to the area with a dosage of 6-562 platelets per square centimeter of the area..
Central Medical Technologies Inc.


01/07/16
20160000064 

Platelet storage and reduced bacterial proliferation in platelet products using a sialidase inhibitor


The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation.
The Brigham And Women's Hospital, Inc.


12/31/15
20150381004 

Insulation arrangement for a high-voltage machine


A widening bar, which has main insulation with first and second layers is used as an insulation arrangement for a high-voltage machine. The first layer has platelet-shaped mica particles and the second layer has platelet-shaped aluminum oxide particles.
Siemens Aktiengesellschaft


12/31/15
20150375928 

Breaking system applied in capsules for espresso machines, tea and other solubles, made of thermoplastic material, aluminium or its derivatives


Breaking system to be applied in the area where the water enters and the infusion exits the capsule. The surface from the bottom of the cup presents interior creases, reducing the thickness of the wall and limited areas of rupture or breaking, that is caused by the normal pressure water pump.
GalvÃo & Noronha, Lda.


12/31/15
20150374697 

Organic compounds


The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery..
Icahn School Of Medicine At Mount Sinai


12/24/15
20150369817 

Platelet biomarkers in cancer diagnosis


The present embodiments relate generally to the field of cancer diagnostics. More specifically the embodiments relate to platelet derived biomarkers used for diagnosis of cancer or cancer progression, as well as prognosis and improved treatment..
Neoproteomics Ab


12/24/15
20150368302 

Designed ankyrin repeat proteins binding to platelet-derived growth factor


New designed ankyrin repeat proteins with binding specificity for pdgf-bb are described, as well as nucleic acids encoding such pdgf binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.. .
Molecular Partners Ag


12/24/15
20150367608 

Composite flame barrier laminate for a thermal and acoustic insulation blanket


A multilayer laminate comprising in order, a polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, an adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c. And an inorganic refractory layer wherein the refractory layer comprises platelets in an amount at least 85% by weight with a dry areal weight of 15 to 50 gsm and has a residual moisture content of no greater than 10 percent by weight..
E I Du Pont De Nemours And Company


12/24/15
20150367064 

Platelet concentrating system


A method for more effectively concentrating blood platelets for use in medical procedures includes providing preparation and concentrating tubes. Anticoagulated whole blood is added to the preparation tube, which is centrifuged to separate red blood cells from a platelet plasma suspension the platelet plasma suspension is aspirated and loaded into the concentrating tube, which is itself centrifuged to separate the platelet plasma suspension into platelet poor plasma and platelet rich plasma layers.

12/24/15
20150366912 

Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation.
Chang Gung Medical Foundation, Linkou Branch


12/24/15
20150366239 

Production fish feed enriched with polar lipids and method to enrich farmed fishes


The present disclosure relates to the production of fish feed with olive ingredients intended for farmed freshwater and saltwater fish, and the aquaculturing of freshwater and saltwater fish which are fortified or enriched through their feeding with ingredients derived from olive processing byproducts. The invention also relates to the fortified or enriched fish as such.
Nireus Aquaculture S.a


12/24/15
20150366182 

Platelet storage methods and compositions for same


Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a rac inhibitor, a cdc42 inhibitor, a rhoa inhibitor, or a combination thereof.
Children's Hospital Medical Center


12/17/15
20150361453 

Platelets transfected by exogenous genetic material and platelet microparticles obtained by said transfected platelets, the preparation and uses thereof


Platelets transfected with exogenous genetic material and microparticles deriving from said transfected platelets are discussed. The platelets have a high percentage of transfection and are able to transport and to transfect acceptor cells with genetic material and then are used for example in gene and cell therapy.

12/17/15
20150360956 

Production of graphene nanoplatelets by oxidative anhydrous acidic media


In some embodiments, the present disclosure pertains to methods of producing graphene nanoplatelets by exposing graphite to a medium to form a dispersion of graphite in the medium. In some embodiments, the exposing results in formation of graphene nanoplatelets from the graphite.
William Marsh Rice University


12/17/15
20150359540 

Selectively delivering particles into the distal portion of the left gastric artery


Methods and apparatuses for embolizing an artery in a living subject using a catheter are disclosed. The catheter has a lumen and also has a balloon located near the distal end of the catheter.
Endobar Solutions, Llc


12/10/15
20150355167 

Apparatus and testing multi-function and drug response of centrifugal microfluidic-based platelets


The present invention relates to an apparatus and method for testing a multi-function and a drug response of platelet based on a centrifugal microfluidics. The testing apparatus according to the present invention may include: a rotatable disk; a sample chamber arranged at the center of the disk such that a blood sample is accommodated therein; stirring chambers respectively connected to the sample chamber in multiple radial directions so as to introduce a shear flow in the blood sample; microchannels connected to the stirring chambers such that adhesion and cohesion of platelets occur during the 44 movement of the blood sample; and a waste sample chamber in which the blood sample is accommodated after passing through the microchannels.
Korea University Research And Business Foundation


12/10/15
20150353701 

Expandable vinyl aromatic polymers comprising platelet needle coke particles


Expandable vinyl aromatic polymers may contain comminuted needle petroleum coke with a polymodal particle size distribution. Foams obtained from such expandable vinyl aromatic polymers have a reduced thermal conductivity at a reduced foam density..
Total Research & Technology Feluy


12/10/15
20150353495 

Nicotinamides as jak kinase modulators


The present invention is directed to compounds of formula i and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.


12/10/15
20150353184 

Composite flame barrier laminate for a thermal and acoustic insulation blanket


A multilayer laminate for use as a flame barrier in an aircraft comprising (i) a polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, (ii) an adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c., (iii) an inorganic refractory layer, and (iv) aramid paper comprising from 50 to 90 weight percent of aramid fibers and from 10 to 50 weight percent of meta-aramid binder wherein the inorganic refractory layer of (iii) comprises platelets in an amount of at least 85% by weight with a dry areal weight of 15 to 50 gsm and a residual moisture content of no greater than 10 percent by weight.. .
E I Du Pont De Nemours And Company


12/10/15
20150351892 

Treatment inhibiting platelet attachment and articles treated thereby


A device such as a medical device and a method for making same provides a surface modified by beam irradiation, such as a gas cluster ion beams or a neutral beam, to inhibit or delay attachment or activation or clotting of platelets.. .
Exogenesis Corporation


12/03/15
20150344677 

Effect pigments


A high chroma effect pigment includes a platelet substrate and an optical coating formed on the platelet substrate. The optical coating includes a first high refractive index layer, a second high refractive index layer on the first high refractive index layer, and a diffused third material having a range of diffusion between 100% to partial diffusion in the first high refractive index layer, the second high refractive index layer, or both the first and the second high refractive index layers.
Basf Se


12/03/15
20150344541 

Platelet targeted treatment


The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets..
Platelet Targeted Therapeutics, Llc


12/03/15
20150344533 

Nucleic acid modulators of glycoprotein vi


The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein gpvi to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore gpvi function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation.
Regado Biosciences, Inc.


12/03/15
20150342982 

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms


Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as et..
Geron Corporation


11/26/15
20150338424 

Apparatus and platelet function and drug repsonse testing based on microfluidic chip


The present invention relates to an apparatus and a method for testing a function and a drug response of a platelet based on a microfluidic chip. The apparatus for test comprises a measuring device containing a blood sample and measuring aggregation and adhesion of a platelet generated by flow of the blood sample; and a fluid driving device which is connected to the measuring device and generates a oscillating shear flow of the blood sample.
Korea University Research And Business Foundation


11/26/15
20150338330 

Method for comprehensive assessment of platelet aggregation


A method for comprehensively and quantitatively analyzing platelet aggregability, and stability and persistence of platelet aggregates, which method comprises the steps of: reacting a platelet-activating reagent with blood in a closed container; injecting a liquid which is not mixable with blood into the container using a pump connected to a first end of the container, thereby pushing the mixture of the platelet-activating reagent and the blood out from the container and allowing the mixture to pass through a filter in a filter device connected to a second end of the container; and measuring the pressure exerted on the pump.. .
Fujimori Kogyo Co., Ltd.,


11/26/15
20150337137 

Method of manufacture of particles with controlled dimensions


A process for the preparation of particles with controlled dimensions comprising the steps of: (i) providing a laminar substrate having a patterned surface comprising a micro-relief repeat pattern comprising one or more discrete cells, each cell consisting of a floor portion and walls having a height (hw); (ii) depositing organic or inorganic material onto the patterned surface and into the cells to provide a thickness (t) of the deposited material wherein t≦hw (iii) stripping the deposited organic or inorganic material from the surface of the substrate; and (iv) collecting the particles formed from said organic or inorganic material; and a composition obtainable from said process comprising a plurality of particles (p), wherein the number (n) of particles in said composition is at least 10, wherein said particles (p) are platelets exhibiting a planar geometry which is circular or which is made up of a number (x) of planar (y)-sided polygon(s), wherein x is from 1 to 20 and y is at least 3 wherein if x is greater than 1 then said planar (y)-sided polygons are fused along one or more sides thereof, wherein the width (wp) of the platelets (p) at their widest point is no more than about 250 pm and the thickness of the platelets (p) is in the range of 10 nm to 50 nm.. .

11/26/15
20150337101 

Rigid polystyrene foams, a molded body and insulation containing rigid polystyrene foams


Rigid polystyrene foams contain thermally treated non-graphitic anthracite coke particles. Such athermanous materials permit a more energy-efficient grinding process, wherein the ground particles are yielded in the desired platelet form and these ground particles also disperse well in a polystyrene matrix.
Sgl Carbon Se


11/26/15
20150337039 

Mac-1 antibodies and uses thereof


A method of treating a subject having or at risk of a disease or disorder associated with aberrant leukocyte-platelet interactions includes administering to the subject a therapeutically effective amount of a monoclonal antibody or antigen binding portion thereof that specifically binds to at least one of seq id no: 1, seq id no: 2, or seq id no: 3 to inhibit leukocyte arrest on adherent platelets in the subject.. .
Case Western Reserve University


11/26/15
20150337021 

Molecules, compositions and methods to treat organ scarring


The present disclosure provides molecules, compositions and methods for treating scarring in organs. The molecules, compositions and methods treat scarring by modulating the wnt, platelet-derived growth factor receptor (pdgfr), transforming growth factor-beta (tgf3) and/or connective-tissue growth factor (ctgf) signaling pathways..
Children's Hospital Medical Center


11/26/15
20150335717 

Synthetic platelets


A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von willebrand factor-binding peptides (vbps), collagen-binding peptides (cbps) and an active platelet gpiib-iiia-binding peptides (gbps).. .
Case Western Reserve University


11/26/15
20150335682 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a stem cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) agonist. In some embodiments the stem cell is a pluripotent stem cell.
Trustees Of Boston University


11/26/15
20150335681 

Biocomposites having viable stem cells and platelets and methods for making and using the same


Aspects of the present disclosure include methods for preparing biocomposites having viable stem cells and platelets. Methods according to certain embodiments include combining a composition that contains viable stem cells with a composition the contains platelets in a centrifugation vessel, subjecting the centrifugation vessel to a force of centrifugation to produce two or more fractions such that each fraction includes a component having different density and collecting a fraction from the centrifuge vessel that includes the platelets and viable stem cells.
Microaire Surgical Instruments, Llc


11/26/15
20150335680 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a stem cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) agonist. In some embodiments the stem cell is a pluripotent stem cell.
Trustees Of Boston University


11/26/15
20150335670 

Medical applications of notoginsenoside fc


A method for preparing a platelet aggregation inhibitor, a blood coagulation inhibitor, and a pharmaceutical composition or a food for preventing or treating thrombotic diseases, includes applying notoginsenoside fc.. .
Shanghai University Of Traditional Chinese Medicine


11/19/15
20150333424 

Electrical connectors and methods of making same


An electrical connector includes a contact for making electrical connection with a corresponding contact of a mating connector. The electrical connector further includes a carbon layer disposed on a contact surface of the contact.
3m Innovative Properties Company


11/19/15
20150329820 

Cell culture media compositions for primary cells


platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ecs) and mammalian endothelial progenitor cells (epcs), in particular human ecs (huecs) and human epcs (huepcs), such as primary huecs and primary huepcs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors.
Mayo Foundation For Medical Education And Research


11/19/15
20150328388 

Device for separating/housing blood components and preparing platelet-rich plasma


Provided are: a device that is for separating/housing blood components and that can more easily and aseptically separate/house platelet-rich plasma; and a method for preparing platelet-rich plasma. The device for separating/housing blood components is provided with: a blood storage section; a component housing section for housing a component that is part of blood; and a linking tube that joins the blood storage section and the component housing section.
Jms Co., Ltd.


11/12/15
20150322514 

Diagnostic markers for platelet function and methods of use


Disclosed herein are biomarkers of platelet function and methods for assessing platelet function in response to anti-platelet therapy and for determining a prognosis, diagnosis, or risk identification in a patient by detecting at least one biomarker of platelet function in the patient as well as determining amounts thereof. The biomarkers may be used to identify a patient as a candidate for treatment with an antiplatelet agent and to monitor and adjust antiplatelet therapy in a patient..
Duke University


11/12/15
20150322480 

Method for measuring thrombin generation


It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a p2y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity..
Daiichi Sankyo Company, Limited


11/12/15
20150320904 

Tissue sealant in which collagen and fibrin are mixed, and preparing same


The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material.
Sewoncellontec Co., Ltd.


11/05/15
20150315449 

Composite material containing graphene


In one aspect, a composite material is disclosed herein that includes graphene platelets dispersed in a matrix. In some cases, the graphene platelets are randomly oriented within the matrix.
The Boeing Company


11/05/15
20150315285 

Human cdr-grafted antibody and antibody fragment thereof


A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. .
Kyowa Hakko Kirin Co., Ltd.


11/05/15
20150313944 

Methods for production of platelets from pluripotent stem cells and compositions thereof


Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hescs) and induced pluripotent stem cells (ipscs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells.
Ocata Therapeutics, Inc.


11/05/15
20150313943 

Method of preparing platelet solution replaced with artificial preservation solution


μp: viscosity of the platelet solution (pa·s).. .

11/05/15
20150313924 

Methods of improving rnai in well-differentiated airway epithelia


The present invention relates to methods of reducing a level of a target mrna in a well-differentiated airway epithelial cell by contacting the cell with a facilitating agent followed by contacting the cell with a therapeutic rnai agent, wherein the facilitating agent comprises a platelet-activating factor receptor (pafr) ligand.. .
University Of Iowa Research Foundation


11/05/15
20150313900 

Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity


The present invention relates to a regimen for the administration of a pyrimidyl-aminobenzamide of formula i as defined herein for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the bcr-abl oncoprotein, the cell transmembrane tyrosine kinese receptor c-kit, ddr1 (discoidin domain receptor 1), ddr2 (discoidin domain receptor 2) or pdgf-r (platelet derived growth factor receptor) kinase activity.. .

10/29/15
20150307513 

Composition for the treatment or prophylaxis of thrombosis or embolism


The description herein relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the description herein comprises administration of an acyl derivative of the formula iia in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation.
Ipca Laboratories Limited


10/29/15
20150306238 

Bacteria targeting nanoparticles and related methods of use


The present invention relates to bacteria-targeting nanoparticles and related methods of use. In particular, the present invention relates to dendrimer nanoparticles conjugated with vancomycin and/or polymixin (e.g., polymixin b, polymixin e).
The Regents Of The University Of Michigan


10/29/15
20150305324 

Platelet concentrate preservation method


A method and a platelet concentrate preservation device for platelet concentrate storage. A method includes at least partially saturating platelet concentrate xenon, and storing the platelet concentrate at less than 15 c in a generally horizontal position.
Advanced Preservations Technologies, Llc


10/22/15
20150305212 

Graphene nanoplatelets- or graphite nanoplatelets-based nanocomposites for reducing electromagnetic interferences


A process for producing gnp-based polymeric nanocomposites for electromagnetic applications such as shielding and/or absorption of the energy associated to electromagnetic fields envisages a plurality of steps that include: controlled synthesis, for optimizing the morphological and electrical properties thereof, of graphene nanoplatelets (gnps) to be used as nanofillers in a polymeric matrix; selection of the polymeric matrix so as to optimize its chemical compatibility with the type of gnps thus obtained; production via the solution-processing technique of gnp-based polymeric nanocomposites with dielectric permittivity and electric conductivity controlled and predictable via the equivalent-effective-medium model by calibrating the parameters of the model for the specific type of polymeric matrix and gnps used.. .
UniversitÀ Degli Studi Di Roma "la Sapienza"


10/22/15
20150299790 

Novel assay for monitoring glucose balance and oxidative stress


The invention relates to diagnostic and prognostic assays, particularly to methods of determining the metabolic state of a subject. More specifically, the invention provides assays and methods comprising determining the level of m rna of uncoupling protein 2 (ucp2) specifically in platelets of the subject.
The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center


10/22/15
20150299759 

Method for thrombogenicity testing of implanted medical device


A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined..
Abbott Cardiovascular Systems Inc.


10/22/15
20150299651 

Cell culture supplements


The invention relates to cell culture supplements based on a platelet rich plasma fraction and a platelet poor plasma fraction. The supplements increase cell proliferation rate, improve selection of clonogenic cells, proliferation of cells from biopsies from elderly patients, maintenance of cell differentiation potential, and in vitro expansion of cell cultures also starting from an extremely low number of initially plated cells.
Biorigen International Sa


10/22/15
20150299301 

Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor


The present invention relates to polypeptides comprising at least one single domain antibody directed against vwf, vwf a1 domain, a1 domain of activated vwf, vwf a3 domain, gpib and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g.
Ablynx N.v.


10/22/15
20150297595 

Inhibitors of syk and jak protein kinases


The present invention is directed to compounds of formula i-v and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.


10/15/15
20150294752 

Graphene masterbatch


Disclosed is a graphene masterbatch including a base resin, electrically conductive carbon black, graphene nanoplatelets with modified surface and a dispersant. The modified surface of graphene nanoplatelet is formed by a modifying agent containing a coupling compound so as to possess hydrophobic and hydrophilic functional groups, which help graphene nanoplatelets form chemical bonding with carbon black and the base resin.

10/15/15
20150291609 

Mertk-specific pyrimidine compounds


The present invention includes pyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150291606 

Mertk-specific pyrrolopyrimidine compounds


The present invention includes pyrrolopyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrrolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150291605 

Mertk-specific pyrazolopyrimidine compounds


The present invention includes pyrazolopyrimidine compounds of formula i that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrazolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .



Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.1017

4622

1 - 1 - 101